DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company: 8 sponsored US clinical trials, none currently recruiting.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plaque Psoriasis, with 1 trials.
Upper-quartile sponsor footprint
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219
A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants
NCT06627088
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
NCT06503679
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
NCT06345794
A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
NCT06311656
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
NCT06092931
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
NCT05994807
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
NCT05896527
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Therapeutic Areas
How the DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Plaque Psoriasis (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company: archived-pipeline peers nationwide
Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 archived trials
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company page
8 registered trials is a research-attention snapshot, not an endorsement of DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company or any single study.
- None of DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Plaque Psoriasis is the condition DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Plaque Psoriasis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company pipeline card: 8 registered trials from official public datasets.Report a data error.